Core Laboratories (CLB) Net Income towards Common Stockholders (2022 - 2026)

Core Laboratories' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$753000.0 for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 1191.3% year-over-year to -$753000.0 in Q1 2026; TTM through Mar 2026 was $29.5 million, a 11.25% decrease from a year earlier, with the FY2025 full-year figure at $30.4 million, down 17.04% from the prior year.
• Net Income towards Common Stockholders declined to -$753000.0 in Q1 2026 per CLB's latest filing, from $5.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $22.9 million in Q2 2023 and bottomed at -$8.6 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is $8.4 million (2022), against an average of $7.3 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 239.7% in 2024 and slumped 1191.3% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $9.6 million in 2022, then sank by 189.71% to -$8.6 million in 2023, then soared by 239.7% to $12.0 million in 2024, then sank by 57.23% to $5.1 million in 2025, then plunged by 114.68% to -$753000.0 in 2026.
• Per Business Quant, the three latest CLB Net Income towards Common Stockholders figures stand at -$753000.0 (Q1 2026), $5.1 million (Q4 2025), and $14.5 million (Q3 2025).